U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07857941) titled 'Exploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2' on Feb. 21, 2025.
Brief Summary: Functional dyspepsia (FD) is associated with inflammatory responses caused by the release of histamine from eosinophils and mast cells, leading to increased intestinal mucosal permeability, which is a key pathogenic mechanism.
Meta-analyses have shown that H2 antihistamine drugs are as effective as proton pump inhibitors in treating FD, while H1 antihistamines achieve an efficacy rate of up to 79%. However, there is no research comparing the effects and pathological changes of combined H1/H2 antagonists versus ...